Literature DB >> 7795275

In vitro assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion.

D L Silbergeld1, M R Chicoine, C L Madsen.   

Abstract

Although the antineoplastic efficacy of Taxol against a variety of tumors has been established, it has only recently been used for malignant brain tumors. We evaluated in vitro chemosensitivity of glioblastoma to Taxol and the affect of Taxol on glioblastoma cell locomotion. The clonogenic assay was used to evaluate the chemosensitivity of five human glioblastomas and the C6 rat glioma. Cells exposed to Taxol (0-250 nM) were suspended in agar in capillary tubes. Following incubation, colonies were counted to determine percent survival. All six cell lines demonstrated sensitivity to Taxol (LD50 1 nM to > 250 nM). However, even at concentrations exceeding those achievable clinically, all cell lines had surviving cells, indicating a saturation threshold for Taxol cytotoxicity. Cell locomotion was evaluated using the radial dish assay to determine the rate of egress of cells from a region of high cell density to the periphery. Increasing Taxol concentration caused increased locomotion in all six cell lines (p < 0.0001). Although Taxol has significant cytocidal impact, it increases in vitro locomotion of glioblastoma cells. These findings suggest that the clinical use of Taxol for glioblastoma may slow the growth of bulk disease, but may also lead to increased tumor invasion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795275     DOI: 10.1097/00001813-199504000-00011

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  8 in total

Review 1.  Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review.

Authors:  Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2007-01-04       Impact factor: 4.130

2.  The brain slice chamber, a novel variation of the Boyden Chamber Assay, allows time-dependent quantification of glioma invasion into mammalian brain in vitro.

Authors:  Christian Schichor; Siglinde Kerkau; Theresa Visted; Rudolf Martini; Rolf Bjerkvig; Jörg Christian Tonn; Roland Goldbrunner
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

3.  Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.

Authors:  Ananth K Vellimana; Violette Renard Recinos; Lee Hwang; Kirk D Fowers; Khan W Li; Yonggang Zhang; Saint Okonma; Charles G Eberhart; Henry Brem; Betty M Tyler
Journal:  J Neurooncol       Date:  2012-12-07       Impact factor: 4.130

4.  Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells.

Authors:  Balázs Hegedus; Júlia Zách; András Czirók; József Lövey; Tamás Vicsek
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

5.  Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest.

Authors:  W Roth; B Wagenknecht; C Grimmel; J Dichgans; M Weller
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

6.  Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro.

Authors:  A J Terzis; F Thorsen; O Heese; T Visted; R Bjerkvig; O Dahl; H Arnold; G Gundersen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier.

Authors:  Delara Karkan; Cheryl Pfeifer; Timothy Z Vitalis; Gavin Arthur; Maki Ujiie; Qingqi Chen; Sam Tsai; Gerrasimo Koliatis; Reinhard Gabathuler; Wilfred A Jefferies
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

8.  A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.

Authors:  S A Glynn; P Gammell; M Heenan; R O'Connor; Y Liang; J Keenan; M Clynes
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.